Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,700.00
Ask: 1,800.00
Change: 0.00 (0.00%)
Spread: 100.00 (5.882%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,799.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK Annual Report 2023 on Form 20-F

5 Mar 2024 17:24

RNS Number : 7075F
GSK PLC
05 March 2024
 

Issued: 5 March 2024, London UK

 

GSK plc 2023 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 5 March 2024 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2023. GSK's 2023 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

A hard copy version of the GSK 2023 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2024.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2023, free of charge, by either:

 

(i)

writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if calling from outside the UK);

 

(ii)

writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128 (outside the US); or

 

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria WhyteCompany Secretary5 March 2024

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSQKPBBOBKDKNK
Date   Source Headline
9th Dec 20214:35 pmRNSDirector/PDMR Shareholding
7th Dec 202112:00 pmRNSMedicago/GSK COVID-19 vaccine positive Ph3 data
7th Dec 20217:07 amRNSSotrovimab retains its activity vs Omicron variant
2nd Dec 20217:02 amRNSSotrovimab retains its activity vs Omicron variant
1st Dec 202111:05 amPRNTotal Voting Rights
24th Nov 20214:17 pmRNSDirector/PDMR Shareholding
24th Nov 20214:00 pmRNSGSK publishes provisional 2022 dividend dates
23rd Nov 20213:06 pmRNSDirector/PDMR Shareholding
17th Nov 20217:00 amRNSNucala approved in Europe for more indications
15th Nov 20214:37 pmRNSBlock listing Interim Review
12th Nov 202112:00 pmRNSPhase III IM administration data for sotrovimab
12th Nov 20219:23 amRNSDirector/PDMR Shareholding
10th Nov 202111:28 amRNSDirector/PDMR Shareholding
5th Nov 20215:33 pmRNSGSK shares positive Phase III data for daprodustat
1st Nov 20215:11 pmRNSTotal Voting Rights
27th Oct 20212:23 pmRNSDirector/PDMR Shareholding
27th Oct 202112:00 pmRNS3rd Quarter Results
27th Oct 20219:00 amRNSDirectorate Change
15th Oct 20212:41 pmRNSDirector/PDMR Shareholding
14th Oct 20214:31 pmRNSDirector/PDMR Shareholding
14th Oct 20214:28 pmRNSDirector/PDMR Shareholding
13th Oct 20211:55 pmRNSDirector/PDMR Shareholding
12th Oct 20213:17 pmRNSDirector/PDMR Shareholding
12th Oct 20211:36 pmRNSDirector/PDMR Shareholding
12th Oct 20211:33 pmRNSDirector/PDMR Shareholding
12th Oct 20211:30 pmRNSDirector/PDMR Shareholding
12th Oct 20211:28 pmRNSDirector/PDMR Shareholding
1st Oct 202111:54 amRNSTotal Voting Rights
24th Sep 20215:28 pmRNSDirector/PDMR Shareholding
22nd Sep 20213:58 pmRNSDirector/PDMR Shareholding
20th Sep 20212:42 pmRNSDirector Declaration
13th Sep 20215:26 pmRNSDirector/PDMR Shareholding
9th Sep 20214:42 pmRNSDirector/PDMR Shareholding
7th Sep 20214:54 pmRNSDirector/PDMR Shareholding
3rd Sep 20219:32 amRNSDirector/PDMR Shareholding
1st Sep 202111:44 amRNSTotal Voting Rights
31st Aug 20217:00 amRNSSK bio & GSK start Ph3 Covid-19 vaccine trial
25th Aug 20212:01 pmRNSDirector/PDMR Shareholding
23rd Aug 20214:39 pmRNSDirector/PDMR Shareholding
13th Aug 20219:38 amRNSDirector/PDMR Shareholding - amendment
11th Aug 20212:18 pmRNSDirector/PDMR Shareholding
11th Aug 202112:34 pmRNSDirector/PDMR Shareholding
5th Aug 20219:00 amRNSBlock Listing Application
2nd Aug 20212:23 pmRNSTotal Voting Rights
28th Jul 20215:32 pmRNSDirector/PDMR Shareholding
28th Jul 202112:00 pmRNS2nd Quarter Results
26th Jul 20214:59 pmRNSDirector/PDMR Shareholding
23rd Jul 20212:32 pmRNSBoard Committee Changes
22nd Jul 20212:45 pmRNSCEO Designate of new Consumer Healthcare company
16th Jul 202112:00 pmRNSGSK announces daprodustat phase 3 headline results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.